eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 130 blog entries.
17 10, 2018

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection

2018-10-17T20:58:12+00:00

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection Lambda Antiviral Activity Demonstrated in HDV Infection Currently Dosing Lambda in Combination with Lonafarnib in HDV Infection PALO ALTO, Calif., October 17, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive [...]

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection2018-10-17T20:58:12+00:00
16 10, 2018

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint

2018-10-16T21:16:17+00:00

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint PALO ALTO, Calif., October 16, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and secondary [...]

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint2018-10-16T21:16:17+00:00
16 10, 2018

Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)

2018-10-16T21:09:57+00:00

Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) Primary and Secondary Endpoints Achieved with Statistical SignificanceAvexitide Treatment Reduces Hypoglycemia and Hyperinsulinism PALO ALTO, Calif., October 16, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today [...]

Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)2018-10-16T21:09:57+00:00
25 09, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-09-25T13:50:24+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., September 25, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City. Cantor Fitzgerald 4th [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-09-25T13:50:24+00:00
24 09, 2018

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018

2018-09-24T18:58:05+00:00

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection PALO ALTO, Calif., September 24, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the receipt [...]

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 20182018-09-24T18:58:05+00:00
4 09, 2018

Eiger Announces Positive Meeting with FDA on Progeria

2018-09-04T14:32:10+00:00

Eiger Announces Positive Meeting with FDA on Progeria -  Company advancing plans to file NDA for Lonafarnib in ProgeriaPALO ALTO, Calif., September 4, 2018 – Today, Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a company focused on the development and commercialization of targeted therapies for rare diseases, announced it has received minutes from a pre-investigational new drug [...]

Eiger Announces Positive Meeting with FDA on Progeria2018-09-04T14:32:10+00:00
27 08, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-08-29T18:26:56+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., August 27, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that members of the Eiger management team will participate in multiple investor conferences in September in New York City. Details of [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-08-29T18:26:56+00:00
13 08, 2018

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia

2018-08-13T16:53:51+00:00

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia PALO ALTO, Calif., August 13, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study.  [...]

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia2018-08-13T16:53:51+00:00
10 08, 2018

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results

2018-08-10T13:36:31+00:00

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results  PALO ALTO, Calif., August 10, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months ended June 30, 2018 and provided a business update. Key Achievements 2Q 2018 To [...]

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results2018-08-10T13:36:31+00:00
6 08, 2018

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health

2018-08-06T16:55:38+00:00

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health PALO ALTO, Calif., August 6, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the [...]

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health2018-08-06T16:55:38+00:00